Anders Bröijersén

BioPhausia AB operates as a pharmaceutical company. It markets and distributes original drugs, generic products, and the parallel-imported medicines. The company is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden.

Merz Pharmaceuticals GmbH discovers and develops drugs for the treatment of neurological and psychiatric diseases. Its dermatology products focus on the treatment of scars, acne, hair loss and fungal diseases. In the area of metabolic disturbances, it offers therapies for liver disease and lipid metabolism disorders. The company also offers various OTC products, including cold remedies, skin care products and vitamin supplements under the brand names tetesept and Merz Special. The company is headquartered in Frankfurt am Main, Germany.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden.

KLIFO A/S provides clinical research services. Its services include development plans, protocols, project management, monitoring, data management and statistics, reporting, regulatory affairs, importing, packaging, labeling, and distribution of clinical trials. The company provides services to the pharmaceutical and medical devices industries. KLIFO was founded by Dr. Allan Rosetzsky in 1994 and is headquartered in Copenhagen, Denmark.

Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark.

Part of Holmen AB, Iggesund Paperboard AB is a Swedish company that manufactures and distributes paperboard products. The private company is based in Stockholm, Sweden. The CEO of the company is Annica Bresky.

Phadia AB develops, manufactures and markets blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. The company was founded in 2004 and is headquartered in Uppdala, Sweden.

Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland.

A.A.G. Aalborg Gummivarefabrik A/S is a holding company engage in manufacturing and processing technical rubber products. Its products include sheeting and plates, profiles, gaskets, pur and plastic, stable mats, mats and flooring, polyvinyl chloride doors, and accessories. It also offers items such as vibration insulators, rubber protectors and footings, custom made fender, polyurethane, playgrounds, damper, and scraper flooring solutions. The company was founded on June 29, 1979 and is headquartered in Norresundby, Denmark.

SoliferPolar AB manufactures and wholesales caravans. The company was founded in 1964 and is headquartered in Dorotea, Sweden.

Nycomed AB With a broad portfolio of products and a powerful pipeline, they work in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. Nycomed engaged in all aspects of a product's life, from research and development to customer relations. They also work closely with innovative research-based companies, constantly looking for products with real promise for patients. They believe that everything do matters to someone. So they work carefully to make sure they get what they do right. They focus on results and respond quickly to the needs of patients and healthcare providers, giving them the best possible experience from working with clients. By doing this, they can achieve vision of being the preferred pharmaceutical company.

Immedica Pharma AB provides know-how and access of specialty care medicine and products. It also provides information on regulatory and medical affairs and product distribution. The company is headquartered in Stockholm, Sweden.

Nordic BioSite AB is a leading supplier of research and diagnostic products. Nordic BioSite was founded in 1997 by Yvonne Zar and is currently headquartered in Täby, SE. The Swedish company provides an extensive range of products within numerous research areas and offers unique promotions. The CEO of the company is Camilla Duborn.

KVS Invest AB manages securities. The company is headquartered in Rydeback, Sweden.

Cavastor AB provides consultancy services. The company is headquartered in Rydeback, Sweden.

Gedea Biotech AB provides drugs for the treatment of bacterial and fungal diseases. It develops an antibiotic-free treatment for vaginal fungal infections. The company was founded by Olov Arvid Sterner, Ingrid Helena Strevens, Ulf Christian Ellervik, and Sophie Margareta Manner and is headquartered in Lund, Sweden.

Pollux Pharma AB is a Swedish company that wholesales and distributes pharmaceutical products. The private company is based in Gothenburg, Sweden.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million.